Albumin/interferon alpha 2A fusion protein

Drug Profile

Albumin/interferon alpha 2A fusion protein

Alternative Names: Recombinant human serum albumin/interferon alpha2a fusion protein

Latest Information Update: 16 Feb 2016

Price : $50

At a glance

  • Originator Beijing Bio-Fortune
  • Class Albumins; Antivirals; Interferons; Recombinant fusion proteins
  • Mechanism of Action Interferon alfa 2a stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 16 Feb 2016 No recent reports on development identified - Phase-I/II for Hepatitis B in China (SC)
  • 01 Nov 2014 Beijing Bio-Fortune completes a phase I/II trial in Hepatitis B in China (NCT01997944)
  • 25 Nov 2013 Phase-I/II clinical trials in Hepatitis B in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top